Fulgent Genetics Insider Sells 943 Shares for RSU Withholding; Weighted Avg $21.48
Rhea-AI Filing Summary
Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported a sale of 943 shares of the issuer's common stock on 08/27/2025 to satisfy tax withholding related to restricted stock units that vested from a grant made on 02/26/2024. The shares were sold in multiple transactions at prices ranging from $21.28 to $21.66, with a reported weighted-average sale price of $21.4847. After the reported sale, the reporting person beneficially owned 958,148 shares directly. The Form 4 was signed by an attorney-in-fact, Paul Kim, on 08/28/2025. No derivative transactions or other amendments are disclosed in this filing.
Positive
- Transparent disclosure of the reason for the sale (tax-withholding on vested RSUs) and the original grant date.
- Small disposition relative to holdings: only 943 shares sold versus 958,148 shares retained, indicating continued ownership alignment.
- Price-range provided ($21.28–$21.66) and weighted-average sale price reported ($21.4847).
Negative
- None.
Insights
TL;DR: Insider sale was a tax-withholding sell-to-cover of vested RSUs; the executive retains a large direct stake.
The filing shows a routine sell-to-cover transaction tied to the vesting of restricted stock units granted on 02/26/2024. The number sold (943 shares) is immaterial relative to the reported post-transaction holding (958,148 shares), indicating no change in control or significant cashing out by the officer. The weighted-average price reported is $21.4847, with transaction prices disclosed between $21.28 and $21.66. The use of an attorney-in-fact signature is common for administrative filings. From an investor-impact perspective, this is a non-material, administrative disposition.
TL;DR: Transaction consistent with standard tax-withholding practice; no governance red flags evident.
The sale is explicitly described as occurring to satisfy tax withholding obligations from vested RSUs. The Form 4 discloses the original grant date and references the prior Form 4 reporting the grant, which supports transparency. There are no indications of unusual timing, large-scale disposition, or related-party transactions. Beneficial ownership remains substantial at 958,148 shares, suggesting continued alignment with shareholder interests. Documentation and price-range disclosure meet typical disclosure expectations.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 943 | $21.4847 | $20K |
Footnotes (1)
- The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. The shares were sold in multiple transactions at prices ranging from $21.28 to $21.66, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
